This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Medlab Clinical Croissance future

Future contrôle des critères 2/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Medlab Clinical.

Informations clés

-44.7%

Taux de croissance des bénéfices

-44.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices	15.0%
Taux de croissance des recettes	41.7%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	04 May 2023

Mises à jour récentes de la croissance future

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Nov 22

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

Prévisions de croissance des bénéfices et des revenus

ASX:MDC - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2024	4	-22	N/A	N/A	1
6/30/2023	7	-14	N/A	N/A	1
6/30/2022	2	-8	-9	-9	N/A
3/31/2022	1	-9	-10	-10	N/A
12/31/2021	4	-12	-11	-11	N/A
9/30/2021	4	-12	-11	-11	N/A
6/30/2021	1	-10	-10	-10	N/A
3/31/2021	1	-10	-9	-9	N/A
12/31/2020	1	-11	-8	-8	N/A
9/30/2020	2	-12	-10	-9	N/A
6/30/2020	3	-13	-11	-10	N/A
3/31/2020	4	-12	-11	-11	N/A
12/31/2019	4	-12	-12	-12	N/A
9/30/2019	5	-10	-11	-11	N/A
6/30/2019	5	-8	-11	-10	N/A
3/31/2019	5	-7	-9	-9	N/A
12/31/2018	5	-6	-7	-7	N/A
9/30/2018	4	-5	-6	-6	N/A
6/30/2018	4	-5	-5	-5	N/A
3/31/2018	4	-4	-5	-5	N/A
12/31/2017	5	-4	-5	-5	N/A
9/30/2017	5	-4	-4	-4	N/A
6/30/2017	4	-4	-4	-4	N/A
3/31/2017	4	-4	-4	-4	N/A
12/31/2016	4	-4	-4	-4	N/A
9/30/2016	3	-4	-4	-4	N/A
6/30/2016	3	-3	-4	-4	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: MDC is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: MDC is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: MDC is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: MDC's revenue (41.7% per year) is forecast to grow faster than the Australian market (4.8% per year).

Croissance élevée des revenus: MDC's revenue (41.7% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if MDC's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Medlab Clinical Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance